Raymond James Financial
TRVI icon

Raymond James Financial’s Trevi Therapeutics TRVI Stock Holding History

Raymond James Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Sell
50,000
-50,000
-50% -$727K ﹤0.01% 4735
2026
Q1 		$800K Sell
100,000
-50,000
-33% -$560K ﹤0.01% 4023
2025
Q4 		$1.25M Buy
+150,000
New +$1.73M ﹤0.01% 3634

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Raymond James Financial's TRVI Position: Q2 2026 in Review

Raymond James Financial reduced its Trevi Therapeutics (TRVI) stake by 4.6% in Q2 2026, selling an estimated $1.12M and leaving 1,610,657 shares worth $30M. The position accounts for 0.01% of the portfolio, ranked #1279.

Raymond James Financial first reported a position in TRVI in Q4 2024 and has held it in 7 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Raymond James Financial held 1,610,657 shares of Trevi Therapeutics worth $30M as of Q2 2026.
  • Raymond James Financial sold 77,320 Trevi Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Trevi Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1279 holding.
  • Raymond James Financial first reported a position in Trevi Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.